Clinical Trial Update: RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating RO4929097 in combination with Bevacizumab for progressive or recurrent malignant glioma was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Brain Tumor
• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-07-14